Placebo News and Research

RSS

New research finds anti-inflammatory drugs to be ineffective to prevent Alzheimer’s

Researchers have known for decades that inflammation accompanies Alzheimer's disease brain lesions. Several early studies suggested that "super-aspirins" or Nonsteroidal anti-inflammatory drugs could help avoid the disease.

8 Apr 2019

NSAIDs ineffective for treatment or prevention of Alzheimer's disease

Researchers have known for decades that inflammation accompanies Alzheimer's disease (AD) brain lesions.

5 Apr 2019

New immune-based therapy eliminates HPV in one-third of women with cervical precancerous lesions

A potential new immune-based therapy to treat precancers in the cervix completely eliminated both the lesion and the underlying HPV infection in a third of women enrolled in a clinical trial.

4 Apr 2019

Gout treatment could potentially reduce complications accompanying metabolic syndrome

The drug colchicine, used to treat the arthritic condition gout, could potentially reduce complications accompanying metabolic syndrome, a combination of high blood pressure, high blood sugar and other conditions that increase the risk of heart disease and type 2 diabetes, according to researchers at the National Institutes of Health.

2 Apr 2019

FDA approves new oral drug to treat relapsing forms of multiple sclerosis

The U.S. Food and Drug Administration today approved Mavenclad (cladribine) tablets to treat relapsing forms of multiple sclerosis (MS) in adults, to include relapsing-remitting disease and active secondary progressive disease.

29 Mar 2019

FDA approves treatment for adults with non-radiographic axial spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

28 Mar 2019

Gene transfer technique can combat diabetes-linked heart dysfunction

Researchers with the VA San Diego Healthcare System and the University of California San Diego have shown that a gene transfer technique can combat heart dysfunction caused by diabetes.

28 Mar 2019

Clinical trial examines medicinal cannabis as potential treatment for severe Tourette syndrome

A pioneering clinical trial investigating medicinal cannabis as a potential treatment for people living with severe Tourette syndrome will be conducted by Wesley Medical Research, in Brisbane in Australia, with cannabis supply facilitated by Lambert Initiative for Cannabinoid Therapeutics at University of Sydney.

28 Mar 2019

Common drug may lead to obesity in offspring

Metformin,a common drug used to treat type 2 diabetes, is often used during pregnancy where the mother suffersfrom polycystic ovary syndrome.

27 Mar 2019

Male contraceptive pill crosses the human clinical trial hurdle

Birth control pills have been around for the past six decades but have been for use of women only. A team of researchers this week have announced the success of the first male birth control pill that could safely prevent pregnancy.

27 Mar 2019

FDA approves new drug to treat adults with relapsing forms of MS

The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

27 Mar 2019

Male contraceptive pill shown to be safe and tolerable in phase I trial

A potential new male birth control pill has been declared safe for use after a phase I trial showed that the once-daily capsule works without causing any significant side effects.

26 Mar 2019

Treating women with thyroid antibodies with Levothyroxine do not increase live birth rate

Treating women who have thyroid antibodies, but normal thyroid function, with a medicine called Levothyroxine does not make them more likely to deliver a live baby, new research from the United Kingdom suggests.

25 Mar 2019

Altering gut microbiome may be potential treatment option for PCOS

Symptoms of polycystic ovary syndrome improved with exposure to healthy bacteria in the gut, according to a study in a mouse model of this common women's endocrine disorder.

25 Mar 2019

Research suggests oxytocin as potential new obesity treatment

The hormone oxytocin reduces the communication between different brain areas involved in the cognitive, sensory and emotional processing of food cues that people with obesity demonstrate when they look at high-calorie foods, according to research being presented Monday at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.

25 Mar 2019

Naltrexone implant more effective in reducing relapses in HIV patients with opioid addiction

When patients with HIV who are also battling opioid dependence go without addiction treatment, they are more likely to stop taking their HIV medications than drug-free patients.

22 Mar 2019

First postpartum depression drug gets FDA nod

Sage therapeutics’ Zulresso became the first drug approved for postpartum depression by the United States Food and Drugs Administration (FDA). This cause the shares of Sage to rise by over 5 percent on Tuesday this week.

20 Mar 2019

New study aims to reduce online sexual exploitation of children

On March 26th, the Karolinska Institutet and Karolinska University Hospital in Swedenare launching a new study aimed at reducing online sexual exploitation of children. Recruitment of study participants will take place in forums on the encrypted part of the internet called the darknet.

20 Mar 2019

FDA approves first drug for treatment of postpartum depression in adult women

The U.S. Food and Drug Administration today approved Zulresso (brexanolone) injection for intravenous use for the treatment of postpartum depression in adult women. This is the first drug approved by the FDA specifically for PPD.

20 Mar 2019

Acute doses of synthetic cannabinoid can impair critical thinking and memory

A new study shows that inhaled doses of as little as 2 mg of the synthetic cannabinoid JWH-018 can significantly impair critical thinking and memory, slow reaction times, and increase confusion and dissociation.

19 Mar 2019